Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby A Eyre

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
Oncotarget|January 17, 2019
Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?Toby A Eyre
British Journal of Haematology|June 14, 2026
Where next for BTKi-BCL2i combinations in mantle cell lymphoma?Toby A Eyre
Hematology. American Society of Hematology. Education Program|December 9, 2023
Richter transformation-is there light at the end of this tunnel?Toby A Eyre
British Journal of Haematology|November 5, 2019
Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomasToby A Eyre
British Journal of Haematology|May 19, 2020
Prognostication in Richter syndrome: context is everythingToby A Eyre
Oncotarget|March 23, 2019
Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?Toby A Eyre
Blood Advances|October 28, 2025
CART in MCL: risk and reward?Toby A Eyre
British Journal of Haematology|April 26, 2017
An update for Richter syndrome - new directions and developmentsToby A Eyre, Anna Schuh
Blood|June 24, 2017
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltrationCharlotte K Brierley, Toby A Eyre
British Journal of Haematology|April 1, 2015
Immune checkpoint inhibition in lymphoid diseaseToby A Eyre, Graham P Collins
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
Oncotarget|January 17, 2019
Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?Toby A Eyre
British Journal of Haematology|June 14, 2026
Where next for BTKi-BCL2i combinations in mantle cell lymphoma?Toby A Eyre
Hematology. American Society of Hematology. Education Program|December 9, 2023
Richter transformation-is there light at the end of this tunnel?Toby A Eyre
British Journal of Haematology|November 5, 2019
Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomasToby A Eyre
British Journal of Haematology|May 19, 2020
Prognostication in Richter syndrome: context is everythingToby A Eyre
Oncotarget|March 23, 2019
Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?Toby A Eyre
Blood Advances|October 28, 2025
CART in MCL: risk and reward?Toby A Eyre
British Journal of Haematology|April 26, 2017
An update for Richter syndrome - new directions and developmentsToby A Eyre, Anna Schuh
Blood|June 24, 2017
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltrationCharlotte K Brierley, Toby A Eyre
British Journal of Haematology|April 1, 2015
Immune checkpoint inhibition in lymphoid diseaseToby A Eyre, Graham P Collins
Pageof 16